source
- FDA outlines new onshoring incentives and meeting types for generic drug applicants under GDUFA IVThe FDA released its GDUFA IV commitments, indicating that review timelines for generic drug submissions will remain largely consistent through 2032, mirroring the schedule of the previous five yea…
- Eli Lilly sues six U.S. entities over illegal retatrutide sales, urges broader crackdownEli Lilly announced legal action against six U.S. entities accused of selling its experimental obesity drug retatrutide on the black market. The lawsuits target compounding pharmacies, medical spa…